Targovax R&D Day: New York - October 11, 2018

New York, October 11, 2018

PLEASE JOIN US FOR A KOL EVENT

Leading experts discuss the oncolytic virus landscape and present interim data from Targovax’s ongoing melanoma and mesothelioma trials

 

 

General Agenda

11:30AM-12:00PM
Registration & Lunch

12:00-12:10PM
Welcome Remarks
Øystein Soug, CEO, Targovax

12:10-12:50PM
Oncolytic Virus Overview and Q&A
Dmitriy Zamarin, MD, PhD

12:50-1:30PM
Melanoma: the disease, CPIs, and lack of treatment options; Early ONCOS-102 data
Alexander N. Shoushtari, MD

1:30-1:50PM
Mesothelioma ORR Data
Magnus Jaderberg, CMO, Targovax

1:50-2:00PM
Closing Remarks
Øystein Soug, CEO, Targovax

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Targovax [TRVX:OS] NKr530 MM MCap
En­gi­neered on­co­lyt­ic virus armed w im­mune-sti­m­u­lat­ing trans­genes for pa­tients w solid tu­mors. Ph 1 and Ph 1/2 trials on­go­ing with mul­ti­ple da­ta read­outs in 2018 and 2019. CMO de­vel­oped Yer­voy at BMS. [more in­for­ma­tion]

Location of the Event and Other Places